Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. J Clin Oncol 2012 Feb 10;30(5):e64-8
Date
12/29/2011Pubmed ID
22203760Pubmed Central ID
PMC3295556DOI
10.1200/JCO.2011.38.2614Scopus ID
2-s2.0-84856873458 (requires institutional sign-in at Scopus site) 38 CitationsAuthor List
Subbiah V, Slopis J, Hong DS, Ketonen LM, Hamilton J, McCutcheon IE, Kurzrock RAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAdult
Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Benzenesulfonates
Bevacizumab
Child
Child, Preschool
Drug Synergism
Erlotinib Hydrochloride
Female
Humans
Indoles
Male
Molecular Targeted Therapy
Neurofibromatosis 2
Niacinamide
Phenylurea Compounds
Pyridines
Pyrroles
Quinazolines
Sirolimus
TOR Serine-Threonine Kinases
Treatment Outcome
Valproic Acid
Vascular Endothelial Growth Factor A
Young Adult
